- Home
- MDXH vs APLT Comparison
MDXH vs APLT Comparison
Compare MDXH & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDXH
- APLT
- Stock Information
- Founded
- MDXH 2003
- APLT 2016
- Country
- MDXH Belgium
- APLT United States
- Employees
- MDXH N/A
- APLT N/A
- Industry
- MDXH
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- MDXH
- APLT Health Care
- Exchange
- MDXH Nasdaq
- APLT Nasdaq
- Market Cap
- MDXH 93.1M
- APLT 80.3M
- IPO Year
- MDXH 2021
- APLT 2019
- Fundamental
- Price
- MDXH $1.86
- APLT $0.53
- Analyst Decision
- MDXH Strong Buy
- APLT Buy
- Analyst Count
- MDXH 2
- APLT 7
- Target Price
- MDXH $7.00
- APLT $6.10
- AVG Volume (30 Days)
- MDXH 58.0K
- APLT 3.0M
- Earning Date
- MDXH 02-26-2025
- APLT 03-05-2025
- Dividend Yield
- MDXH N/A
- APLT N/A
- EPS Growth
- MDXH N/A
- APLT N/A
- EPS
- MDXH N/A
- APLT N/A
- Revenue
- MDXH $84,708,000.00
- APLT N/A
- Revenue This Year
- MDXH $28.76
- APLT N/A
- Revenue Next Year
- MDXH $19.91
- APLT $2,622.90
- P/E Ratio
- MDXH N/A
- APLT N/A
- Revenue Growth
- MDXH 33.01
- APLT N/A
- 52 Week Low
- MDXH $1.55
- APLT $0.53
- 52 Week High
- MDXH $3.85
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- MDXH 41.65
- APLT 29.75
- Support Level
- MDXH $1.82
- APLT $0.54
- Resistance Level
- MDXH $2.01
- APLT $0.70
- Average True Range (ATR)
- MDXH 0.09
- APLT 0.06
- MACD
- MDXH 0.01
- APLT 0.06
- Stochastic Oscillator
- MDXH 46.43
- APLT 0.00
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.